Computer Sciences Corporation (CSC) reported second quarter 2010 EPS of $1.40, exceeding the Zacks Consensus Estimate of $1.35. Revenue The company reported second quarter revenue of $4.0 billion, up 4.7% from $4.2 billion reported in the year-ago quarter. The company witnessed new business bookings and sequentially positive revenues across all three of its business segments. North American Public Sector (NPS) revenue was $1.62 billion, up 8.5% from the previous year. Managed Services Sector (MSS) revenue was $1.58 billion, down 12.5% from the previous year. Business Solutions and Services (BSS) revenue was $0.86 billion, down 10.7% from the previous year. New Business The company won $4.58 billion worth of new business awards in the recently concluded quarter. Of the three lines of business, NPS accounted for $3.23 billion, BSS $0.98 billion and MSS $0.37 billion of new business. For the third quarter of fiscal ...

Here are the stocks added to the Zacks #1 Rank ("strong buy") List today:

Atlas Pipeline Holdings LP (AHD) British Sky Broadcasting Group Plc (BSY) Central Garden & Pet Co (CENT) Cohen & Steers Inc (CNS) Companhia Paranaense de Energia (ELP) CPFL Energia SA (CPL) Diamond Management & Technology Consultants Inc (DTPI) Drew Industries Inc (DW) Encore Capital Group Inc (ECPG) EnerSys (ENS) Flowserve Corp (FLS) GlaxoSmithKline Plc (GSK) Ixia (XXIA) Jo-Ann Stores Inc (JAS) Life Time Fitness Inc (LTM) Macquarie Infrastructure Company LLC (MIC) ...

Below are companies with market caps under $250 million from the BioMedReports.com FDA Calendar, which have either pending FDA decisions or pending clinical trial results that may have a major impact on each of the underlying stock prices. A high risk/reward trading approach to consider for speculative traders is investing a small amount of money that you can afford to lose in a basket of stocks included in Extreme FDA and Clinical Trial Calendar Trades, which are highlighted in periodic articles at BioMedReports.com. Another approach is to simply buy such companies well ahead of their expected catalyst dates for a possible stock price increase as the date approaches and trading activity increases.

BioMimetic Therapeutics [BMTI: 9.07, -0.52 (-5.42%)]: On 6/17/09, BMTI announced that it has submitted both the pre-clinical pharmacology/toxicology and quality/manufacturing modules of its Premarket Approval (PMA) application for marketing of Augment Bone Graft

...

Here are the stocks added to the Zacks #1 Rank ("strong buy") List today:

Aaron Rents Inc (RNT) Alliance One International Inc (AOI) Altair Nanotechnologies Inc (ALTI) Best Buy Co Inc (BBY) BioReference Laboratories Inc (BRLI) Chipotle Mexican Grill Inc CL 'B (CMG.B) Citi Trends Inc (CTRN) Claude Resources Inc (CGR) CNS Response Inc (CNSO) DRDGold Ltd (DROOY) Elbit Systems Ltd (ESLT) Empresas ICA SA (ICA) Ezcorp Inc (EZPW) Gander Mountain Co (GMTN) Harmony Gold Mining Co (HMY) Idera Pharmaceuticals Inc (IDRA) InterOil Corp (IOC) Metabasis Therapeutics Inc (MBRX) Nile Therapeutics Inc (NLTX) NPS Pharmaceuticals Inc (NPSP) Park National Corp (PRK) Penwest Pharmaceuticals (PPCO) PetMed Express Inc (PETS) Radio One Inc (ROIAK) Radvision Ltd (RVSN) Regis Corp (RGS) ResMed Inc (RMD) Silgan ...

NPS Pharmaceuticals, Inc. (NPSP) shares have gained more than 11% today on the back of its fourth-quarter report from Friday. The advance has made this company a top-performing Zacks #1 Rank.

< ?DART(15);?> Analysts continue to expect a loss for both this year and next, but those loss estimates have been narrowing over the past 60 days or so. Expectations for this year have advanced to a loss of 61 cents presently from a loss of 65 cents 2 months ago. A month ago, the company was expected to lose 63 cents, as 2 of 3 analysts raised expectations in the past 30 days.

Expectations have improved more dramatically for next year, as loss estimates have narrowed 14 cents in 2 months, including 2 cents in just the past 7 days. Furthermore, analysts expect a loss of 48 cents for next year, compared to a loss

...

It is estimated that the U.S. House of Representatives' construction-related stimulus proposal, released on 15 January 2009, might exceed $160 billion. The following is an outline of the proposal:Transportation:Dept. of Transportation (DOT) federal-aid highways = $30 billion; DOT airport improvement grants = $3 billion; DOT passenger rail = $1.1 billion; DOT transit capital assistance to buy buses, railcars & make facility improvements = $6 billion; DOT transit fixed-guide-way infrastructure = $2 billion; DOT transit capital investment grants for light rail, heavy rail, commuter rail, HOV projects = $1 billion; Army Corps of Engineers (civil works) = $4.5 billion; U.S. Forest Service capital improvement & maintenance = $0.65 billion.Defense-related:Facilities improvements = $4.5 billion; hospitals and ambulatory surgical centers = $3.75 billion; Troop housing and child care centers = $1.55 billion; Reserves and National Guard = $0.40 billion; base realignment and closure environmental cleanup = ...